 |
Photo: Ildong Pharmaceutical Group headquarters building (Courtesy of Ildong Pharmaceutical) |
[Alpha Biz= Paul Lee] Seoul, September 3, 2025 — Kiwoom Securities stated that the recent sharp decline in Ildong Pharmaceutical’s share price, following news of Eli Lilly’s partial suspension of a clinical trial for its oral obesity treatment candidate, appears to reflect excessive market concern rather than fundamentals.
Ildong Pharmaceutical’s stock fell 6.75% in the previous session, after plunging as much as 16.16% intraday. This followed a 3.93% drop on September 2, bringing the two-day decline to 10.41%.
According to Kiwoom Securities analyst Huh Hye-min, investor worries spread after reports that Eli Lilly had partially suspended clinical trials of its next-generation oral GLP-1 candidate, Naperiglifron. This in turn raised concerns about Ildong’s own small-molecule oral obesity treatment candidate.
However, Huh stressed that the suspension of Naperiglifron’s trial was not due to safety or efficacy issues. “Eli Lilly announced positive Phase 3 results for another small-molecule obesity drug candidate, Orforglipron, in April for diabetes patients and in August for obesity patients,” Huh noted. “With Lilly moving forward to file Orforglipron for FDA approval, the company likely decided against redundant R&D investment in Naperiglifron.”
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
